{"id":63013,"date":"2026-04-13T20:04:13","date_gmt":"2026-04-13T12:04:13","guid":{"rendered":"https:\/\/flcube.com\/?p=63013"},"modified":"2026-04-13T20:04:15","modified_gmt":"2026-04-13T12:04:15","slug":"cutia-therapeutics-cu-20101-meets-phase-iii-endpoints-demonstrating-non-inferiority-to-botox-for-glabellar-lines","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63013","title":{"rendered":"Cutia Therapeutics&#8217; CU-20101 Meets Phase III Endpoints, Demonstrating Non-Inferiority to BOTOX for Glabellar Lines"},"content":{"rendered":"\n<p><strong>Cutia Therapeutics<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2487:HKG\">HKG: 2487<\/a>) has announced the successful completion of its pivotal <strong>Phase III clinical trial<\/strong> in China for <strong>CU-20101<\/strong>, its investigational botulinum toxin type A for injection. The study met its primary and secondary endpoints, demonstrating <strong>non-inferiority to BOTOX<\/strong> (onabotulinumtoxinA) in improving moderate to severe glabellar lines (frown lines), with a favorable safety profile and a manufacturing process free of animal-derived components.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-trial-results-summary\">Clinical Trial Results Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result<\/th><th>Assessment Method<\/th><\/tr><\/thead><tbody><tr><td><strong>Primary Efficacy<\/strong><\/td><td>Met non-inferiority vs. BOTOX<\/td><td>On-site Investigator &amp; Participant (Facial Wrinkle Scale &#8211; FWS)<\/td><\/tr><tr><td><strong>Key Secondary Efficacy<\/strong><\/td><td>Supported non-inferiority conclusion<\/td><td>Independent Assessment Committee (IAC) via photographs<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Favorable; comparable to BOTOX<\/td><td>No treatment-related SAEs, deaths, or withdrawals<\/td><\/tr><tr><td><strong>Manufacturing Advantage<\/strong><\/td><td>Animal-component free; no human serum albumin<\/td><td>Eliminates TSE risk and related allergic reactions<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-differentiation-amp-safety\">Product Differentiation &amp; Safety<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Efficacy Parity:<\/strong> The robust data from both on-site and independent photographic assessments confirm that CU-20101 delivers aesthetic results on par with the established market leader, BOTOX.<\/li>\n\n\n\n<li><strong>Enhanced Safety Profile:<\/strong> The absence of <strong>animal-derived materials<\/strong> and <strong>human serum albumin<\/strong> in CU-20101\u2019s manufacturing process is a significant differentiator. This design eliminates the theoretical risk of <strong>transmissible spongiform encephalopathy (TSE)<\/strong> and reduces the potential for associated allergic reactions, offering a compelling safety advantage for patients and clinicians.<\/li>\n\n\n\n<li><strong>Clean Bill of Health:<\/strong> The trial reported no new safety signals, with adverse events mirroring those commonly seen with other botulinum toxin products, further supporting its tolerability.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-implications\">Market Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Competitive Entry:<\/strong> With this positive Phase III data, Cutia Therapeutics is positioned to file for marketing approval in China, aiming to capture a share of the large and growing aesthetic neurotoxin market.<\/li>\n\n\n\n<li><strong>Value Proposition:<\/strong> CU-20101\u2019s combination of proven efficacy and a potentially superior safety profile due to its cleaner manufacturing process could be a key driver for adoption by dermatologists and plastic surgeons.<\/li>\n\n\n\n<li><strong>Global Potential:<\/strong> While the trial was conducted in China, the strong dataset and unique manufacturing approach could form the basis for future international regulatory submissions, challenging Allergan\u2019s (AbbVie) global dominance.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief reports on top-line results from a completed Phase III trial. The data are subject to final statistical analysis and regulatory review. There can be no assurance that CU-20101 will receive marketing approval from the NMPA or any other regulatory authority.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026041300058_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026041300058_c.\"><\/object><a id=\"wp-block-file--media-c6a7e0ce-08b6-4f54-9fa1-230df69bf8b1\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026041300058_c.pdf\">2026041300058_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026041300058_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-c6a7e0ce-08b6-4f54-9fa1-230df69bf8b1\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Cutia Therapeutics (HKG: 2487) has announced the successful completion of its pivotal Phase III clinical&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[17,450,1221,100],"class_list":["post-63013","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-results","tag-cutia-therapeutics","tag-hkg-2487","tag-medical-aesthetics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Cutia Therapeutics&#039; CU-20101 Meets Phase III Endpoints, Demonstrating Non-Inferiority to BOTOX for Glabellar Lines - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Cutia Therapeutics (HKG: 2487) has announced the successful completion of its pivotal Phase III clinical trial in China for CU-20101, its investigational botulinum toxin type A for injection. The study met its primary and secondary endpoints, demonstrating non-inferiority to BOTOX (onabotulinumtoxinA) in improving moderate to severe glabellar lines (frown lines), with a favorable safety profile and a manufacturing process free of animal-derived components.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63013\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cutia Therapeutics&#039; CU-20101 Meets Phase III Endpoints, Demonstrating Non-Inferiority to BOTOX for Glabellar Lines\" \/>\n<meta property=\"og:description\" content=\"Cutia Therapeutics (HKG: 2487) has announced the successful completion of its pivotal Phase III clinical trial in China for CU-20101, its investigational botulinum toxin type A for injection. The study met its primary and secondary endpoints, demonstrating non-inferiority to BOTOX (onabotulinumtoxinA) in improving moderate to severe glabellar lines (frown lines), with a favorable safety profile and a manufacturing process free of animal-derived components.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63013\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-13T12:04:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-13T12:04:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63013#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63013\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Cutia Therapeutics&#8217; CU-20101 Meets Phase III Endpoints, Demonstrating Non-Inferiority to BOTOX for Glabellar Lines\",\"datePublished\":\"2026-04-13T12:04:13+00:00\",\"dateModified\":\"2026-04-13T12:04:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63013\"},\"wordCount\":391,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial results\",\"Cutia Therapeutics\",\"HKG: 2487\",\"Medical aesthetics\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63013#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63013\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63013\",\"name\":\"Cutia Therapeutics' CU-20101 Meets Phase III Endpoints, Demonstrating Non-Inferiority to BOTOX for Glabellar Lines - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-13T12:04:13+00:00\",\"dateModified\":\"2026-04-13T12:04:15+00:00\",\"description\":\"Cutia Therapeutics (HKG: 2487) has announced the successful completion of its pivotal Phase III clinical trial in China for CU-20101, its investigational botulinum toxin type A for injection. The study met its primary and secondary endpoints, demonstrating non-inferiority to BOTOX (onabotulinumtoxinA) in improving moderate to severe glabellar lines (frown lines), with a favorable safety profile and a manufacturing process free of animal-derived components.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63013#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63013\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63013#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cutia Therapeutics&#8217; CU-20101 Meets Phase III Endpoints, Demonstrating Non-Inferiority to BOTOX for Glabellar Lines\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Cutia Therapeutics' CU-20101 Meets Phase III Endpoints, Demonstrating Non-Inferiority to BOTOX for Glabellar Lines - Insight, China&#039;s Pharmaceutical Industry","description":"Cutia Therapeutics (HKG: 2487) has announced the successful completion of its pivotal Phase III clinical trial in China for CU-20101, its investigational botulinum toxin type A for injection. The study met its primary and secondary endpoints, demonstrating non-inferiority to BOTOX (onabotulinumtoxinA) in improving moderate to severe glabellar lines (frown lines), with a favorable safety profile and a manufacturing process free of animal-derived components.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63013","og_locale":"en_US","og_type":"article","og_title":"Cutia Therapeutics' CU-20101 Meets Phase III Endpoints, Demonstrating Non-Inferiority to BOTOX for Glabellar Lines","og_description":"Cutia Therapeutics (HKG: 2487) has announced the successful completion of its pivotal Phase III clinical trial in China for CU-20101, its investigational botulinum toxin type A for injection. The study met its primary and secondary endpoints, demonstrating non-inferiority to BOTOX (onabotulinumtoxinA) in improving moderate to severe glabellar lines (frown lines), with a favorable safety profile and a manufacturing process free of animal-derived components.","og_url":"https:\/\/flcube.com\/?p=63013","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-13T12:04:13+00:00","article_modified_time":"2026-04-13T12:04:15+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63013#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63013"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Cutia Therapeutics&#8217; CU-20101 Meets Phase III Endpoints, Demonstrating Non-Inferiority to BOTOX for Glabellar Lines","datePublished":"2026-04-13T12:04:13+00:00","dateModified":"2026-04-13T12:04:15+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63013"},"wordCount":391,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial results","Cutia Therapeutics","HKG: 2487","Medical aesthetics"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63013#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63013","url":"https:\/\/flcube.com\/?p=63013","name":"Cutia Therapeutics' CU-20101 Meets Phase III Endpoints, Demonstrating Non-Inferiority to BOTOX for Glabellar Lines - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-13T12:04:13+00:00","dateModified":"2026-04-13T12:04:15+00:00","description":"Cutia Therapeutics (HKG: 2487) has announced the successful completion of its pivotal Phase III clinical trial in China for CU-20101, its investigational botulinum toxin type A for injection. The study met its primary and secondary endpoints, demonstrating non-inferiority to BOTOX (onabotulinumtoxinA) in improving moderate to severe glabellar lines (frown lines), with a favorable safety profile and a manufacturing process free of animal-derived components.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63013#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63013"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63013#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Cutia Therapeutics&#8217; CU-20101 Meets Phase III Endpoints, Demonstrating Non-Inferiority to BOTOX for Glabellar Lines"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63013","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63013"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63013\/revisions"}],"predecessor-version":[{"id":63015,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63013\/revisions\/63015"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63013"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63013"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63013"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}